Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005036 · ClinicalTrials.gov registry record · Phase 3
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT00005036: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00005036 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 560 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005036, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for colorectal cancer.
Interventions
- DRUG oxaliplatin
- PROCEDURE quality-of-life assessment
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 1999-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005036
The ClinicalTrials.gov registry entry for NCT00005036 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00005036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005036 about?
NCT00005036 is a clinical study titled "Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer". Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they s...
What is the current status of trial NCT00005036?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 1999-11.
What interventions are being tested in trial NCT00005036?
The interventions under investigation include: oxaliplatin (DRUG), quality-of-life assessment (PROCEDURE), fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005036?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.